entertainment -WSS

entertainment

author：entertainment 2025-09-06 03:40:03 - browse：839

The building exterior of AstraZeneca, a pharmaceutical and biopharmaceutical company, under cloudless blue sky — coverage from STAT — Adobe

WILMINGTON, Del. — Wednesday was the first time that a federal judge asked questions in-person of drug industry lawyers who are trying to stop Medicare from negotiating drug prices. It didn’t go well for them.

AstraZeneca’s lawyers argued that Medicare’s new powers amount to a taking of their property rights without due process. But Colm Connolly, chief judge of the U.S. District Court of Delaware, said he doesn’t understand how the law deprives AstraZeneca of its property. He asked Catherine Stetson, who represents AstraZeneca, multiple times to explain what property the company would lose due to Medicare price negotiation. Stetson said it’s both the patent and the drug that’s subject to the patent.

“You’re free to do what you want,” Connolly said, adding that drug companies don’t have to sell to Medicare. “You may not make as much money.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： MD Anderson's Padmanee Sharma responds to research credit suit

focus

WSS

Vir antibody drug aimed at influenza A fails in clinical trial

Researchers tackle phage therapy hurdles for wider adoption

Wildfires rage amid heat wave in Greece, prompting evacuations and call for European support

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

A new drug could help frostbite victims avoid its ravages

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

hotspot

entertainment

explore

How to save PrEP access — and even expand it

New CMS data security rules will hurt Medicare, Medicaid research

As demand for Covid shots wanes, Moderna seeks its next success

Measles policy set amid Florida outbreak alarms vaccine proponents

Medicare details structure of new drug price negotiation program

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

BioMarin wins approval for gene therapy to treat hemophilia A

Vir antibody drug aimed at influenza A fails in clinical trial

Guidelines to prevent youth baseball injuries need more muscle

Driven by the pandemic, applicants flood public health schools

hotspot

As AI regulations shape up, health tech startups beg for clarity

Tocagen's brain cancer gene therapy trial continues. Investors worry

Measles policy set amid Florida outbreak alarms vaccine proponents

Judge rejects Trump's request to move Stormy Daniels hush

Tesla recalling nearly 16,000 of its 2021

A Q&A with Gavi’s Seth Berkley on vaccines, Covid, and more

focus

explore

focus

focus